Pathways influencing left ventricular hypertrophy in hemodialysis patients

心脏几何形状异常在接受透析和治疗的患者中很常见 导致每年15%-20%的高死亡率。频繁的血液透析 Network的目标是以随机的方式测试更频繁的透析(两者都是以 夜间透析和每日短期透析)将改善患者的心脏几何形状和 他们对身体健康的主观看法。结合艾伯塔省的肾脏 疾病网络，我们的研究小组可以访问243份储存的血清样本 参与频繁血液透析网络和艾伯塔省肾脏的患者 疾病网络试验。本研究应用程序将检查储存的血液 从这些参与者中抽取样本，分析频繁透析与常规透析的效果(S) 对血液中的一组物质(称为生物标志物)进行标准透析，这 与心脏几何结构异常的发展有关。为了获得更多的利益 对频繁透析与标准透析影响背后的生物学的理解 透析对心脏发育的影响，我们还将检查来自大鼠心脏的细胞是否会 将这些细胞暴露于血清样本后，改变特定基因的表达 心脏几何形状有改善或恶化的患者 频繁血液透析网络或艾伯塔省肾脏疾病网络试验。 因此，本申请有两个具体目的： 目的1：我们将调查生物标志物在常见病患中的水平 血液透析网络和艾伯塔省肾脏疾病网络试验与类型的关系 分配的透析次数(频率与标准)及其心脏几何构型的变化。 目的2：我们将检测来自大鼠心脏的细胞是否会在 暴露于心脏几何构型进展患者和患者的血清 在艾伯塔省的频繁血液透析网络期间心脏几何形状得到改善 肾脏疾病网络试验。 我们的研究团队收集了世界上最大的生物样本，这些样本来自 世界各地强化血液透析试验的参与者。我们已经组装了 完成拟议研究目标所需的临床和科学专业知识。这个 这项辅助研究提案的结果将为我们提供对 改善患者健康的机制和潜在的治疗目标 北美的透析。

Abnormal heart geometry is common among patients receiving dialysis and contributes to the high annual mortality rate of 15-20%. The Frequent Hemodialysis Network aims to test in a randomized fashion if more frequent dialysis (both in the form of nightly dialysis and short daily dialysis) will improve our patients¿ heart geometry and their subjective view of their physical health. In combination of the Alberta Kidney Disease Network, our research team has access to stored serum samples from 243 patients who participated in the Frequent Hemodialysis Network and the Alberta Kidney Disease Network Trials. The present research application will examine stored blood samples from these participants to analyse the effect(s) of frequent dialysis versus standard dialysis on a panel of substances in the blood (known as biomarkers), which are linked with the development of abnormal heart geometry. In order to gain further understanding of the biology behind the impact of frequent dialysis versus standard dialysis on heart development, we will also examine if cells derived from rat hearts will change the expression of specific genes after exposing these cells to serum samples of patients who have either improvement or deterioration of heart geometry during the Frequent Hemodialysis Network or Alberta Kidney Disease Network Trials. The present application therefore has two specific aims: Aim 1: We will investigate the blood levels of biomarkers in participants of the Frequent Hemodialysis Network and Alberta Kidney Disease Network Trials in relation to the type of dialysis (frequent versus standard) assigned and their changes of heart geometry. Aim 2: We will examine if cells derived from rat hearts will express different genes after exposure to serum from patients whose heart geometry progressed and from patients whose heart geometry improved during the Frequent Hemodialysis Network or Alberta Kidney Disease Network Trials. Our research team has the largest collection of biological samples derived from participants of intensive hemodialysis trials worldwide. We have assembled the necessary clinical and scientific expertise to complete the proposed study aims. The results from this ancillary study proposal will provide unique biological insights into the mechanisms and potential therapeutic targets to improve the health of patients receiving dialysis in North America.